Experts say the FDA should carefully evaluate multi-cancer blood screening tests, the article reports.

Regulators must decide how to oversee assays that claim to detect many cancers from a single draw.

A Houston facility already offers a commercial blood draw said to screen for more than fifty cancers.

Doctors warn the assays have limits, including false positives and unnecessary follow-up procedures.

Oregon Health and Science University researchers are studying whether the methods truly help patients.

Investors have piled into diagnostic startups, drawing comparisons to past biotech booms like Moderna.

Federal agencies face pressure to balance innovation with patient safety standards.

Clear evidence thresholds are needed before unproven early-detection claims go mainstream.

Read the full article for more details on multi-cancer blood test oversight.